Excess of Veno-Occlusive Disease in a Randomized Clinical Trial on a Higher Trigger for Red Blood Cell Transfusion after Bone Marrow Transplantation: A Canadian Blood and Marrow Transplant Group Trial

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 3, 2013, Pages 468-473

  Robitaille, Nancy ^a   Lacroix, Jacques ^a   Alexandrov, Lubomir ^a   Clayton, Lucy ^a   Cortier, Marion ^a   Schultz, Kirk R ^b   Bittencourt, Henrique ^a   Duval, Michel ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b BC CHILDREN S HOSPITAL   (Canada)

Author keywords

Hematopoietic stem cell transplantation; Hemoglobin levels; Red blood cell transfusion; Sinusoidal obstruction syndrome; Veno occlusive disease

Indexed keywords

HEMOGLOBIN;

ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ASCITES; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; LIVER FAILURE; MALE; MULTICENTER STUDY; MYELOABLATIVE CONDITIONING; PLEURA EFFUSION; PORTAL VEIN THROMBOSIS; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SCHOOL CHILD; VEIN OCCLUSION;

ADOLESCENT; ASCITES; BONE MARROW TRANSPLANTATION; CHILD; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBINS; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MYELOABLATIVE AGONISTS; MYELODYSPLASTIC SYNDROMES; PLEURAL EFFUSION; RISK FACTORS; THROMBOSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84873741460     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.12.002     Document Type: Article

References (52)

1. Mossad S.B., Longworth D.L., Goormastic M., et al. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 1996, 18:265-271.
2. Offner F., Schoch G., Fisher L.D., et al. Mortality hazard functions as related to neutropenia at different times after marrow transplantation. Blood 1996, 88:4058-4062.
3. Nosanchuk J.D., Sepkowitz K.A., Pearse R.N., et al. Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma. Bone Marrow Transplant 1996, 18:355-359.
4. Toogood I.R., Ekert H., Smith P.J. Controlled study of hypertransfusion during remission induction in childhood acute lymphocytic leukaemia. Lancet 1978, 2:862-864.
5. de Montpellier C., Cornu G., Rodhain J., et al. Myeloid stem cell kinetics in children hypertransfused during remission induction of acute lymphoblastic leukemia. Blood Cells 1982, 8:439-444.
6. Firkin F.C., Hays E.F., Cline M.J. Effect of hypertransfusion on granulopoiesis in bone marrow depression: studies in the irradiated mouse. Br J Haematol 1977, 35:225-231.
7. Smith P.J., Jackson C.W., Dow L.W., et al. Effect of hypertransfusion on bone marrow regeneration in sublethally irradiated mice. I. Enhanced granulopoietic recovery. Blood 1980, 56:52-57.
8. Smith P.J., Jackson C.W., Whidden M.A., Edwards C.C. Effect of hypertransfusion on bone marrow regeneration in sublethally irradiated mice. II. Enhanced recovery of megakaryocytes and platelets. Blood 1980, 56:58-63.
9. Bishop M.R., Tarantolo S.R., Geller R.B., et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000, 96:80-85.
10. Keever-Taylor C.A., Klein J.P., Eastwood D., et al. Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: differential effects of growth factor type and role of CD34(+) cell dose. Bone Marrow Transplant 2001, 27:791-800.
11. Przepiorka D., Smith T.L., Folloder J., et al. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 2001, 97:3405-3410.
12. Ringden O., Labopin M., Gorin N.C., et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004, 22:416-423.
13. Schriber J.R., Chao N.J., Long G.D., et al. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood 1994, 84:1680-1684.
14. Volpi I., Perruccio K., Tosti A., et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 2001, 97:2514-2521.
15. Kasbia G., Al-Gahtani F., Tay J., et al. Reduced hemoglobin on day of peripheral blood progenitor cell collection is associated with low graft content of vascular progenitors and increased toxicity after autologous hematopoietic stem cell transplantation. Transfusion 2008, 48:2421-2428.
16. Tinmouth A., Hutton B., Fergusson D., et al. Effect of pre-transplant hemoglobin and platelet counts on transfusion requirements and survival in allogeneic transplantation. Transfusion 2005, 45:141A.
17. Xenocostas A., Yee A., Wong C.J., et al. RBC transfusion requirements after allogeneic marrow transplantation: impact of the before-transplant Hb level on transfusion and early survival. Transfusion 2003, 43:373-382.
18. Lind M., Vernon C., Cruickshank D., et al. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 2002, 86:1243-1249.
19. Tay J., Tinmouth A., Fergusson D., Allan D. Transfusion of red cells in hematopoietic stem cell transplantation (TRIST): study protocol for a randomized controlled trial. Trials 2011, 12:207.
20. Lacroix J., Hebert P.C., Hutchison J.S., et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med 2007, 356:1609-1619.
21. Kirpalani H., Whyte R.K., Andersen C., et al. The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. J Pediatr 2006, 149:301-307.
22. Hebert P.C., Wells G., Blajchman M.A., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999, 340:409-417.
23. Coppell J.A., Brown S.A., Perry D.J. Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Rev 2003, 17:63-70.
24. Wadleigh M., Ho V., Momtaz P., Richardson P. Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Curr Opin Hematol 2003, 10:451-462.
25. Carreras E., Bertz H., Arcese W., et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998, 92:3599-3604.
26. McDonald G.B., Sharma P., Matthews D.E., et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984, 4:116-122.
27. Sanders J.E., Buckner C.D., Clift R.A., et al. Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation. Bone Marrow Transplant 1988, 3:11-19.
28. Radich J.P., Sanders J.E., Buckner C.D., et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993, 11:304-313.
29. Wadleigh M., Richardson P.G., Zahrieh D., et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003, 102:1578-1582.
30. Jones R.J., Lee K.S., Beschorner W.E., et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987, 44:778-783.
31. Moscardo F., Sanz G.F., de La Rubia J., et al. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection. Bone Marrow Transplant 2001, 27:983-988.
32. Soiffer R.J., Dear K., Rabinowe S.N., et al. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation 1991, 52:1014-1019.
33. Ringden O., Ruutu T., Remberger M., et al. A randomized trial comparing busulfan vs total body irradiation in allogeneic marrow transplant recipients with hematological malignancies. Transplant Proc 1994, 26:1831-1832.
34. Dalle J.H., Wall D., Theoret Y., et al. Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results. Bone Marrow Transplant 2003, 32:647-651.
35. Krivoy N., Hoffer E., Lurie Y., et al. Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children. Curr Drug Saf 2008, 3:60-66.
36. Essell J.H., Thompson J.M., Harman G.S., et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 1992, 79:2784-2788.
37. Hagglund H., Remberger M., Klaesson S., et al. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998, 92:4568-4572.
38. Nevill T.J., Barnett M.J., Klingemann H.G., et al. Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 1991, 9:1224-1232.
39. Lapierre V., Mahe C., Auperin A., et al. Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children. Transplantation 2005, 80:314-319.
40. Klaesson S., Ringden O., Ljungman P., et al. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?. Transplantation 1995, 60:1225-1230.
41. Sullivan K.M., Kansu E., Storer B., et al. Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation. Biol Blood Marrow Transplant 1998, 4:20-26.
42. Cordonnier C., Chevret S., Legrand M., et al. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 2003, 139:8-18.
43. Coppell J.A., Richardson P.G., Soiffer R., et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant 2010, 16:157-168.
44. Bell E.F., Strauss R.G., Widness J.A., et al. Randomized trial of liberal versus restrictive guidelines for red blood cell transfusion in preterm infants. Pediatrics 2005, 115:1685-1691.
45. Bearman S.I. Avoiding hepatic veno-occlusive disease: what do we know and where are we going?. Bone Marrow Transplant 2001, 27:1113-1120.
46. Whillier S., Raftos J.E., Sparrow R.L., Kuchel P.W. The effects of long-term storage of human red blood cells on the glutathione synthesis rate and steady-state concentration. Transfusion 2011, 51:1450-1459.
47. Beck C., Dubois J., Grignon A., et al. Incidence and risk factors of catheter-related deep vein thrombosis in a pediatric intensive care unit: a prospective study. J Pediatr 1998, 133:237-241.
48. Wadhwa M., Seghatchian M.J., Dilger P., et al. Cytokine accumulation in stored red cell concentrates: effect of buffy-coat removal and leucoreduction. Transfus Sci 2000, 23:7-16.
49. Sweeney J., Kouttab N., Kurtis J. Stored red blood cell supernatant facilitates thrombin generation. Transfusion 2009, 49:1569-1579.
50. Hod E.A., Zhang N., Sokol S.A., et al. Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation. Blood 2010, 115:4284-4292.
51. Karam O., Tucci M., Toledano B.J., et al. Length of storage and in vitro immunomodulation induced by prestorage leukoreduced red blood cells. Transfusion 2009, 49:2326-2334.
52. Koshkaryev A., Zelig O., Manny N., et al. Rejuvenation treatment of stored red blood cells reverses storage-induced adhesion to vascular endothelial cells. Transfusion 2009, 49:2136-2143.